GSK Beats Earnings Estimates but Battles Soft Sales and Patent Problems
Published . Updated .
This report is about the broad US market.
Directly affected
- GSK Gsk-6.3% 10d
Named in this report.
Indirectly affected
- DIA SPDR Dow Jones Industrial Average ETF-1.7% 30d
SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “earnings estimates” (the broad US market) in this story.
- QQQ Invesco QQQ+0.9% 30d
Invesco QQQ: it is a broad US stock-market fund. Linked by “earnings estimates” (the broad US market) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Gsk belongs to, so it often moves with news about it.
- NVS Novartis AG+1.3% 17d
Novartis AG is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+4.9% 30d
AstraZeneca is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S-7.3% 30d
Novo Nordisk A/S is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+7.4% 8d
Roivant Sciences is a peer of Gsk in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| GSK | -1.79% | -0.43% | base | -4.34% | -4.51% | after close | after close |
| DIANo price data for this ticker | — | — | — | — | — | — | — |
| QQQ | +0.56% | -2.36% | base | +0.61% | -1.05% | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| NVSNo price data for this ticker | — | — | — | — | — | — | — |
| AZNNo price data for this ticker | — | — | — | — | — | — | — |
| NVONo price data for this ticker | — | — | — | — | — | — | — |
| SNYNo price data for this ticker | — | — | — | — | — | — | — |
| ROIVNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
GSK Beats Earnings Estimates but Battles Soft Sales and Patent Problems Barron's
Source: Barron's
This story
| Company | When | Move | Status |
|---|---|---|---|
| GSK | that day | -4.34% | final price |
| GSK | the next day | -4.51% | final price |
| GSK | three days earlier | -0.43% | final price |
| GSK | five days earlier | -1.79% | final price |
| QQQ | that day | +0.61% | final price |
| QQQ | the next day | -1.05% | final price |
| QQQ | three days earlier | -2.36% | final price |
| QQQ | five days earlier | +0.56% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 62 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 48 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 58 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 63 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“GSK Beats Earnings Estimates but Battles Soft Sales and Patent Problems” scores 12 out of 100. The score uses 1 sources.